Dados B3 › ONCO3 × HYPE3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | ONCO3 | HYPE3 | year |
|---|---|---|---|
| ROE | -179.1% | 9.7% | 2025 |
| ROIC | -23.2%! | 8.8%! | 2025 |
| ROA | -40.0% | 4.8% | 2025 |
| Gross margin | 31.1% | 59.0% | 2025 |
| EBIT margin | -34.7% | 22.9% | 2025 |
| Net margin | -64.0% | 15.5% | 2025 |
| Net debt/EBITDA | 17.39x | 3.64x | 2024 |
| Current ratio | 0.56x | 1.47x | 2025 |
| Revenue growth (1y) | -7.8% | 3.4% | 2025 |
| Revenue growth (5y CAGR) | 23.0% | 13.5% | 2025 |
| Piotroski F-Score | 3/9 | 7/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | ONCO3 | HYPE3 | year |
|---|---|---|---|
| P/E | -0.42x | 11.30x | 2025 |
| P/B | 1.68x | 1.08x | 2025 |
| EV/EBITDA | — | 10.17x | 2025 |
| FCF yield | -19.0% | 13.1% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:54 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it